JF
KROS icon

Jump Financial’s Keros Therapeutics KROS Stock Holding History

Jump Financial’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$556K Sell
50,393
-110,743
-69% -$1.71M 0.01% 1188
2025
Q4 		$3.28M Buy
+161,136
New +$2.83M 0.04% 501
2025
Q2 		– Sell
-103,826
Closed -$1.06M – 1980
2025
Q1 		$1.06M Buy
+103,826
New +$1.21M 0.01% 803
2024
Q4 		– Sell
-15,503
Closed -$900K – 1839
2024
Q3 		$900K Buy
15,503
+1,822
+13% +$90K 0.02% 841
2024
Q2 		$625K Buy
+13,681
New +$735K 0.01% 1039
2023
Q3 		– Sell
-7,283
Closed -$293K – 2066
2023
Q2 		$293K Buy
+7,283
New +$319K 0.01% 1319
2022
Q4 		– Sell
-8,344
Closed -$314K – 1828
2022
Q3 		$314K Sell
8,344
-13,634
-62% -$473K 0.01% 1123
2022
Q2 		$607K Buy
+21,978
New +$964K 0.03% 763

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Jump Financial's KROS Position: Q1 2026 in Review

Jump Financial reduced its Keros Therapeutics (KROS) stake by 69% in Q1 2026, selling an estimated $1.71M and leaving 50,393 shares worth $556K. The position accounts for 0.01% of the portfolio, ranked #1188.

Jump Financial first reported a position in KROS in Q2 2022 and has held it in 8 quarters since. The position peaked at $3.28M in Q4 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Jump Financial held 50,393 shares of Keros Therapeutics worth $556K as of Q1 2026.
  • Jump Financial sold 110,743 Keros Therapeutics shares in Q1 2026, an estimated $1.71M.
  • Keros Therapeutics made up 0.01% of Jump Financial's portfolio in Q1 2026, its #1188 holding.
  • Jump Financial first reported a position in Keros Therapeutics in Q2 2022 and has held it in 8 quarters since.
  • Jump Financial's Keros Therapeutics position peaked at $3.28M in Q4 2025.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Jump Financial's 13F filing for Q1 2026, filed 14 May 2026.